bioethanol, biofuel Biofuels: study challenges EUs tank or...A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EUs climate strategy. The study challenges … more ➔
ADC Therapeutics raises US$200m in private... Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, … more ➔
bioeconomy, EuropaBio, European Biotech week Valuating biotechs benefitsEuropean Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bioeconomy, industry association EuropaBio celebrated … more ➔
CureVac inks $1.7bn deal on mRNA cancer va...mRNA cancer therapeutics specialist CureVac AG has baged US$50m upfront and is eglible to receive up to US$1.7bn in development milestones plus royalties for the development of five commercial cancer … more ➔
Ablynx prices global offeringBelgian Nanobody® producer Ablynx NV said it aims to raise US$175m of its ordinary shares in a global offering, comprised of a public offering of American Depositary Shares ("ADS") in the … more ➔
HPV vaccines: Cochrane Centres complaint...A complaint against the EMAs handling of a referral procedure relating to potential side effects of Sanofi/MSDs HPV vaccine Gardasil and GSKs HPV jab Cervarix promoted by the Nordic … more ➔
CHMP upgrades Roches lung cancer drug Al...The European Medicines Agency (EMA) has upgraded Roches Alecensa (Alectinib) from second-line to first-line treatment for patients with locally advanced of metastasing ALK-positive non-small cell lung … more ➔
InflaRX raises US$55m in Series D roundGerman infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance … more ➔
Targovax reports 100% one-year survival in... Norwegian Targovax ASA (Oslo) has reported tremendous safety, immunogenicity, and one-year survival data, of in the modified cohort of the TG01 trial in resected pancreatic cancer patients. more ➔
Sanofi invests €170m to expand flu jab f...Sanofi is investing €170m to expand its vaccine manufacturing site in Val de Reuil, France, which produces 900 million vaccine doses worldwide each year. more ➔
